GEN3018
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for GEN3018, covering 2026-04-08 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) [Phase 1]